
IconOVir Bio: A preclinical biotech firm innovating personalized oncolytic virus cancer therapies.
Founded with a mission to cure cancer and restore life to every patient, IconOVir Bio is a preclinical-stage biotechnology company focused on developing advanced oncolytic virus therapies. The company aims to overcome the limitations of earlier generations of oncolytic viruses, providing personalized cancer treatments. IconOVir Bio's innovative platform is designed to enhance the efficacy and specificity of these therapies, offering new hope for patients battling cancer.
IconOVir Bio has attracted notable investors and industry experts who believe in its potential to revolutionize cancer treatment. While still in the preclinical stage, the company has made significant strides in developing its proprietary oncolytic virus platform. Its impact lies in the promise of more effective and personalized cancer therapies, potentially transforming the landscape of oncology and improving patient outcomes worldwide.

Unleash Immuno Oncolytics
unleash.bio

Vyriad
vyriad.com

Virion Therapeutics
viriontx.com

Humane Genomics
humanegenomics.com

Dnatrix
dnatrix.com

Viriom
viriom.com

OncoMyx Therapeutics
oncomyx.com

Cynvec
cynvec.com

Precision Virologics

Imanis Life Sciences
imanislife.com

Toragen
toragen.com

Viracta Therapeutics
viracta.com

Nextbiotics
next-biotics.com

Oncolix

OncoPrecision
oncoprecision.bio
Companies similar to IconOVir Bio include Unleash Immuno Oncolytics, Vyriad, Virion Therapeutics and Humane Genomics.
IconOVir Bio was founded in 2018.
IconOVir Bio's headquarters is located in San Diego, CA, US.
IconOVir Bio's most recent funding round was for $77M (USD) in January 2021.
As of Jan 5, 2021, IconOVir Bio has raised a total of $77M (USD).
IconOVir Bio has 8 employees as of Feb 4, 2024.